Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor α Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)Jun Li, Joseph A. Tino, Sean Chen et al.|Journal of Medicinal Chemistry|2010Cited by 41
Novel Peroxisome Proliferator-Activated Receptor α Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor AgonistRanjan Mukherjee, Rai Ajit K. Srivastava, Kenneth T. Locke et al.|Journal of Pharmacology and Experimental Therapeutics|2008Cited by 35
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132)Yan Shi, Qi Wang, Wang Ying et al.|Journal of Medicinal Chemistry|2022Cited by 11
Synthesis and structure–activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARα selective activators- PPARα and PPARγ selectivity modulationXiang‐Yang Ye, Joseph A. Tino, Stephanie Chen et al.|Bioorganic & Medicinal Chemistry Letters|2010Cited by 10
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective AgonistYan Shi, Joseph A. Tino, Jun Li et al.|ACS Medicinal Chemistry Letters|2016Cited by 6